Abstract
Prostate cancer possesses its unique feature of low proliferation rate and slow growth. Ca2+-induced apoptosis is not dependent on cell cycle progression and targeting this pathway could circumvent the problems encountered using current cytotoxic chemotherapies for prostate cancer. Hypoxia-inducible factor 1α (HIF-1α) is another novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides, known inhibitors of the alpha-subunit of sarcolemmal Na+K+-ATPase, were recently found to block tumor growth via the inhibition of HIF-1α synthesis. Thus, cardiac glycosides disrupt two important cellular pathways and, therefore, may be useful as an anticancer therapy. This review will focus on HIF-1α and calcium signaling as novel cancer drug targets in prostate cancer. The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed.
Keywords: HIF-1α, Calcium, Prostate cancer, digoxin, cardiac glycosides
Current Cancer Drug Targets
Title: HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides
Volume: 9 Issue: 7
Author(s): J. Lin, S. Denmeade and M. A. Carducci
Affiliation:
Keywords: HIF-1α, Calcium, Prostate cancer, digoxin, cardiac glycosides
Abstract: Prostate cancer possesses its unique feature of low proliferation rate and slow growth. Ca2+-induced apoptosis is not dependent on cell cycle progression and targeting this pathway could circumvent the problems encountered using current cytotoxic chemotherapies for prostate cancer. Hypoxia-inducible factor 1α (HIF-1α) is another novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides, known inhibitors of the alpha-subunit of sarcolemmal Na+K+-ATPase, were recently found to block tumor growth via the inhibition of HIF-1α synthesis. Thus, cardiac glycosides disrupt two important cellular pathways and, therefore, may be useful as an anticancer therapy. This review will focus on HIF-1α and calcium signaling as novel cancer drug targets in prostate cancer. The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed.
Export Options
About this article
Cite this article as:
Lin J., Denmeade S. and Carducci A. M., HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides, Current Cancer Drug Targets 2009; 9 (7) . https://dx.doi.org/10.2174/156800909789760249
DOI https://dx.doi.org/10.2174/156800909789760249 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Biomarkers for Colorectal Cancer: Identification Through Proteomics
Current Proteomics Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Current Cancer Drug Targets QSAR Multi-Target in Drug Discovery: A Review
Current Computer-Aided Drug Design Mitochondria-Associated Membranes (MAMs): A Novel Therapeutic Target for Treating Metabolic Syndrome
Current Medicinal Chemistry A Review on the Sex Differences in Organ and System Pathology with Alcohol Drinking
Current Drug Abuse Reviews The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Trifunctional Protein Defects: Molecular Basis and Novel Therapeutic Approaches
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry Tumor Stroma Manipulation By MSC
Current Drug Targets Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy